Lead Product(s) : Mazdutide,Dulaglutide
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Least squares mean changes from baseline to week 12 in HbA1c levels were −1.46%, −2.23% and −1.66% for patients receiving IBI362 (mazdutide) in cohort 1,2 and 3, respectively (−1.98% for dulaglutide).
Product Name : IBI362
Product Type : Peptide
Upfront Cash : Inapplicable
June 29, 2022
Lead Product(s) : Mazdutide,Dulaglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dulaglutide
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AWARD-PEDS results presented at ADA's 82nd Scientific Sessions® and simultaneously published in the New England Journal of Medicine demonstrate A1C reductions of up to 1.5% for Trulicity (Dulaglutide) compared to placebo in this underserved population.
Product Name : Trulicity
Product Type : Peptide
Upfront Cash : Inapplicable
April 06, 2022
Lead Product(s) : Dulaglutide
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dulaglutide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study consisted primarily of people with multiple cardiovascular risk factors without established cardiovascular disease. REWIND showed a significant risk reduction in MACE-3, a composite endpoint of nonfatal myocardial infarction, non-fatal stroke o...
Product Name : Trulicity
Product Type : Peptide
Upfront Cash : Inapplicable
September 22, 2020
Lead Product(s) : Dulaglutide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dulaglutide
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Additional Doses of Trulicity® (dulaglutide) for the Treatment of Type 2 Diabetes
Details : The approval expands the label of once-weekly Trulicity to include 3.0 mg and 4.5 mg doses based on data from AWARD-11. The phase 3 trial showed the additional doses led to further benefits in A1C and body weight reduction when compared to Trulicity 1.5 ...
Product Name : Trulicity
Product Type : Peptide
Upfront Cash : Inapplicable
March 09, 2020
Lead Product(s) : Dulaglutide
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
